Hello, My 80 year old parent is diagnosed with extrapatic cholangiocarcinoma roughly a little less than 3 months...

CholangiocarcinomaNovember 6, 2026Written by Navis AI

Navigating Treatment Decisions for Extrahepatic Cholangiocarcinoma

I'm sorry to hear about your parent's diagnosis. Your questions about seeking additional opinions and treatment coordination are important ones that many families face. Let me address each of your concerns systematically.

1) Why Patients Seek Opinions at [facility removed]s

According to NCCN Guidelines for Biliary Tract Cancers, bile duct cancers are complex and relatively rare. The guidelines specifically recommend:

"NCCN experts recommend being treated at a center that has experience with gallbladder cancer" and bile duct cancers.

Common reasons patients seek additional opinions include:

  • Expertise with rare cancers: Extrahepatic cholangiocarcinoma requires specialized surgical and medical oncology expertise
  • Access to clinical trials: Major centers often have trials for targeted therapies or novel combinations not available locally
  • Multidisciplinary tumor boards: These centers routinely review complex cases with hepatobiliary surgeons, medical oncologists, radiation oncologists, and pathologists together
  • Advanced biomarker testing: Comprehensive molecular profiling may identify actionable mutations

The NCCN guidelines emphasize that "hospitals that perform many surgeries often have better results," which applies to both surgical and systemic therapy expertise.

Tell us what’s going on with cholangiocarcinoma. 2 free answers, then a free account.

2) How Treatment Coordination Actually Works

Based on Cancer Patient Lab webinar experiences and NCCN guidance, there are several common models:

Model 1: Consultation Only

  • You travel to the major center for initial evaluation and treatment planning
  • Molecular testing and tumor board review occur there
  • Treatment is administered locally with your oncologist following the major center's recommendations
  • Periodic follow-up visits (every 3-6 months) at the major center

Model 2: Hybrid Care

  • Initial treatment cycles at the major center to establish baseline response
  • Transition to local oncologist for ongoing standard therapy
  • Return to major center if disease progresses or for clinical trial enrollment

Model 3: Clinical Trial Enrollment

  • If you enroll in a clinical trial, requirements vary by protocol
  • Some trials require all treatment at the sponsoring center
  • Others allow local administration after initial cycles
  • From webinar evidence: "Most trials need everything to be done here. We had the NCI MATCH trial for one of my patients... but Duke had the same trial, and so we just sent him to Duke."

Practical considerations from NCCN:

  • "Every trial has different rules... Some have travel paid for, and some don't, depending on how big the company is"
  • Most centers can coordinate care with local oncologists once a treatment plan is established

3) Standard Treatment vs. Targeted Therapy Sequencing

Your parent's recommended regimen (gemcitabine/cisplatin + durvalumab) is exactly what NCCN guidelines recommend as preferred first-line therapy for unresectable extrahepatic cholangiocarcinoma.

According to NCCN Guidelines (2026):

For unresectable tumors, preferred therapies are:

  • Durvalumab with Gemcitabine and Cisplatin
  • Pembrolizumab with Gemcitabine and Cisplatin

However, biomarker testing should happen BEFORE or CONCURRENT with starting treatment, not after. Here's why:

Critical Timing Issue:

The NCCN guidelines state: "Before receiving any treatment, you might have a staging laparoscopy or exploratory surgery to gain knowledge about the amount and location of your cancer" and "A biopsy and biomarker testing will be done before treatment is started."

Actionable mutations that could change first-line treatment include:

  • FGFR2 fusions (10-15% of intrahepatic, less common in extrahepatic)
  • IDH1 mutations (targeted by ivosidenib)
  • BRAF V600E mutations (targeted by dabrafenib + trametinib)
  • NTRK fusions (rare but highly actionable)
  • HER2 amplifications (targeted by trastuzumab + pertuzumab)
  • MSI-H/dMMR status (may respond better to immunotherapy alone)

What You Should Do NOW:

Request comprehensive molecular profiling immediately from the gallbladder tissue that was removed. According to NCCN:

"A sample of your tumor or blood from your biopsy may be tested to see if the cancer cells have any specific mutations. Some mutations, such as NTRK and RET gene fusions or microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR), FGFR2, IDH1, or BRAF V600E mutations, can be targeted with specific therapies."

Ask your oncologist:

  1. "Has comprehensive next-generation sequencing (NGS) been ordered on the gallbladder tissue?"
  2. "Are we testing for FGFR2, IDH1, BRAF, NTRK, HER2, and MSI-H/dMMR status?"
  3. "How long will results take, and can we wait for them before starting treatment?"

From webinar evidence, patients who had molecular testing done at major centers like BostonGene, Caris, or Tempus often discovered actionable mutations that changed their treatment approach.

4) Recommended Facilities in Your Region

Given your location in Southern California, you have excellent options:

Tier 1: NCCN Member Cancer Centers Near You

City of Hope National Medical Center (Duarte, CA)

  • Duarte, California
  • Closest major NCCN center to most of Southern California
  • Strong hepatobiliary program
  • Extensive clinical trial portfolio

UC San Diego Moores Cancer Center (La Jolla, CA)

  • Comprehensive bile duct cancer program
  • Active in cholangiocarcinoma research

UCLA Jonsson Comprehensive Cancer Center (Los Angeles, CA)

  • Major hepatobiliary surgery and medical oncology program

USC Norris Comprehensive Cancer Center (Los Angeles, CA)

  • Not NCCN member but strong regional program
  • Mentioned in webinar as having physicians willing to consider off-label approaches

Tier 2: Nearby NCCN Centers (Reasonable Travel)

Mayo Clinic Arizona (Phoenix/Scottsdale)

  • 5-[address removed] or 1-hour flight
  • Excellent for second opinions
  • Strong multidisciplinary approach
  • From webinar: "Mayo Rochester has Dr. [removed] DeAndre, an integrated oncologist who recommended many alternative therapies"

Stanford Cancer Institute (Stanford, CA - Bay Area)

  • 6-hour drive or 1-hour flight from Southern California
  • Leading research in cholangiocarcinoma

Tier 3: Worth Considering for Complex Cases

MD Anderson Cancer Center (Houston, TX)

  • Largest cancer center in the US
  • Most extensive cholangiocarcinoma program
  • From webinar: Multiple references to MD Anderson's phase 1 trials and hepatobiliary expertise
  • Consider if: Local options don't have appropriate clinical trials or if disease progresses

Memorial Sloan Kettering (New York, NY)

  • Leading bile duct cancer research
  • Extensive targeted therapy trials

5) Specific Action Steps for Your Situation

Immediate (This Week):

  1. Request comprehensive molecular profiling from the gallbladder tissue:

    • Ask for NGS panel that includes at minimum: FGFR2, IDH1, BRAF, NTRK, HER2, MSI/MMR status
    • Companies like Caris, Tempus, Foundation Medicine, or Guardant360 (if tissue insufficient)
    • Turnaround time: typically 10-14 days
  2. Schedule consultation at City of Hope or UCLA while waiting for molecular results:

    • These are 1-2 hour drives for most Southern California residents
    • Can often get appointments within 1-2 weeks
    • Bring: All pathology reports, imaging CDs, treatment summaries
  3. Ask your local oncologists:

    • "Can we wait 2 weeks for molecular testing before starting treatment, or is the disease too aggressive?"
    • "Would you be willing to coordinate care with [City of Hope/UCLA/Mayo] if they recommend a different approach?"
    • "Are there any clinical trials you're aware of for my parent's situation?"

Your next question, already answered

Tap to keep going. 2 free answers, then a free account.

Ask Navis about your case

That answer is general. Ask about your specific situation. Answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Sources & medical oversight

  • Built by OpenCancer’s team of physician-scientists and cancer survivors.
  • Last updated November 6, 2026. Informational only — not a substitute for your oncology team.

Question asked:

Hello, My 80 year old parent is diagnosed with extrapatic cholangiocarcinoma roughly a little less than 3 months back, and underwent surgery only to find out it’s unresectable, but they did remove gallbladder for tissue testing, saw two oncologist locally and both recommended to start with gem / cis and Durvalumab Can I ask what drove the rest of the folks to seek other opinions at [facility removed] or MD Anderson? For those who went for the treatment, did you actually get all the treatment from there? Or they cooperated with the local oncologist? Did everyone start with this treatment option before going to targeted therapy based on NGS results? I am in Southern California so my closest is Mayo Clinic in Phoenix, which other facilities would you recommend? TIA

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

More questions about Cholangiocarcinoma